Holders — by stockHoldings — by fund
ANDERA PARTNERS
Everything this manager disclosed owning in US-listed stocks — its complete Form 13F portfolio · as of 2026-06-30 · filed with the SEC up to 45 days after quarter end · CIK 0001757283
$206.5M
disclosed book value
8
positions
33.6%
largest position share
Positions, as of 2026-06-30
top 8 of 8 · 13F covers long US-listed positions only — cash, bonds, private and foreign stakes are not disclosed · PUT/CALL tags = options positions (share-equivalents), not shares held
| # | Issuer | Shares | Value | % of book |
|---|---|---|---|---|
| 1 | KESTRA MED TECHNOLOGIES LTD | 2.7M | $69.4M | 33.6% |
| 2 | MLYSMINERALYS THERAPEUTICS INC | 1.6M | $42.9M | 20.8% |
| 3 | AVLNAVALYN PHARMACEUTICALS INC | 929,824 | $30.6M | 14.8% |
| 4 | AGMBAGOMAB THERAPEUTICS NV | 1.5M | $20.0M | 9.7% |
| 5 | EVMNEVOMMUNE INC | 1.4M | $18.5M | 9% |
| 6 | IVAINVENTIVA SA | 3.6M | $13.7M | 6.7% |
| 7 | ABVXABIVAX SA | 78,125 | $10.4M | 5% |
| 8 | NYXOAH S A | 522,057 | $882,276 | 0.4% |
Source: SEC Form 13F-HR, reporting period 2026-06-30. Values are the manager's filed June-30-style quarter-end marks, not live prices. Research, not investment advice.